Early trial tests new hope for Tough-to-Treat blood cancer
NCT ID NCT03055286
Summary
This early-stage study tested the safety and initial effectiveness of a new drug, CWP232291, when given with the chemotherapy drug cytarabine. It was for adults whose acute myeloid leukemia (AML) had returned or did not respond to prior treatments. The trial was terminated early and aimed to find the right dose and see if the combination could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Songpa-Gu, South Korea
-
Samsung medical center
Seoul, Gangnam-gu, South Korea
-
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Washington
Seattle, Washington, 98195, United States
Conditions
Explore the condition pages connected to this study.